IV Vitamin C in Adults With Sepsis: A Bayesian Reanalysis of a Randomized Controlled Trial
- PMID: 37026849
- DOI: 10.1097/CCM.0000000000005871
IV Vitamin C in Adults With Sepsis: A Bayesian Reanalysis of a Randomized Controlled Trial
Abstract
Objectives: The Lessening Organ Dysfunction with Vitamin C trial showed a harmful effect of vitamin C on 28-day death or persistent organ dysfunction. To maximize interpretation, we present a post hoc Bayesian reanalysis.
Design: Bayesian reanalysis of a randomized placebo-controlled trial.
Setting: Thirty-five ICUs.
Patients: Adults with proven or suspected infection, vasopressor support, and no more than 24 hours of ICU admission.
Interventions: Patients were allocated to receive either vitamin C (50 mg/kg of body weight) or placebo every 6 hours for up to 96 hours.
Measurements and main results: The primary outcome was the composite of death or persistent organ dysfunction (i.e., vasopressor use, invasive mechanical ventilation, or new renal replacement therapy) at 28 days. We used Bayesian log-binomial models with random effects for hospital site and varying informative prior beliefs for the effect of vitamin C to estimate risk ratios (RRs) with 95% credible intervals (Crls) in the intention to treat population (vitamin C, 435 patients; placebo, 437 patients). Using weakly neutral priors, patients allocated to vitamin C had a higher risk of death or persistent organ dysfunction at 28 days (RR, 1.20; 95% Crl, 1.04-1.39; probability of harm, 99%). This effect was consistent when using optimistic (RR, 1.14; 95% Crl, 1.00-1.31; probability of harm, 98%) and empiric (RR, 1.09; 95% Crl, 0.97-1.22; probability of harm, 92%) priors. Patients allocated to vitamin C also had a higher risk of death at 28 days under weakly neutral (RR, 1.17; 95% Crl, 0.98-1.40; probability of harm, 96%), optimistic (RR, 1.10; 95% Crl, 0.94-1.30; probability of harm, 88%), and empiric (RR, 1.05; 95% Crl, 0.92-1.19; probability of harm, 76%) priors.
Conclusions: The use of vitamin C in adult patients with proven or suspected infection and vasopressor support is associated with high probability of harm.
Copyright © 2023 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.
Conflict of interest statement
Dr. Adhikari’s institution received funding from the Lotte and John Hecht Memorial Foundation. The remaining authors have disclosed that they do not have any potential conflicts of interest.
Comment in
-
Vitamin C and Sepsis: Is Bayesian Reanalysis Useful to Translate the Results of Frequentist Randomized Trials?Crit Care Med. 2023 Aug 1;51(8):1100-1102. doi: 10.1097/CCM.0000000000005939. Epub 2023 Jul 13. Crit Care Med. 2023. PMID: 37439646 No abstract available.
-
Apples and Oranges-All 'Vitamin C' May Not Be Created Equal.Crit Care Med. 2023 Dec 1;51(12):e281-e282. doi: 10.1097/CCM.0000000000006042. Epub 2023 Nov 16. Crit Care Med. 2023. PMID: 37971351 No abstract available.
References
-
- Rudd KE, Johnson SC, Agesa KM, et al.: Global, regional, and national sepsis incidence and mortality, 1990–2017: Analysis for the Global Burden of Disease Study. Lancet. 2020; 395:200–211
-
- Singer M, Deutschman CS, Seymour CW, et al.: The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016; 315:801–810\
-
- Amrein K, Oudemans-van Straaten HM, Berger MM: Vitamin therapy in critically ill patients: Focus on thiamine, vitamin C, and vitamin D. Intensive Care Med. 2018; 44:1940–1944
-
- Agarwal A, Basmaji J, Fernando SM, et al.: Parenteral vitamin C in patients with severe infection: A systematic review. NEJM Evidence. 2022; 1:9
-
- Lamontagne F, Masse M-H, Menard J, et al.: Intravenous vitamin C in adults with sepsis in the intensive care unit. N Engl J Med. 2022; 386:2387–2398
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical